Apreo Health is an emerging clinical-stage medical device company dedicated to restoring health and quality of life to patients afflicted with severe emphysema, an advanced form of Chronic Obstructive Pulmonary Disease (COPD). In 2018 COPD was the second leading cause of death in United States of America(1) behind Ischemic Heart Disease, with over 8,000 deaths due to emphysema in 2023(2). Apreo Health’s first product, the Apreo BREATHE Airway Scaffold is a novel implant designed to gently release air trapped in affected hyper-inflated lungs. Apreo Health is dedicated to pioneering safe, transformative solutions for lung disease. We serve patients with passion, integrity and a commitment to restoring their health and quality of life. Apreo is a privately held company headquartered in Menlo Park, CA., USA. The BREATHE Airway Scaffold is an investigational device and is limited to Federal (or US) investigational use. It is to be exclusively used in clinical investigations. 1 - https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death 2 - https://wonder.cdc.gov/controller/datarequest/D158;jsessionid=D4265629C7ECA176FDA9D2256A45
Location: United States
Total raised: $130M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.08.2025 | Series B | $130M | F-Prime Ca... |
Mentions in press and media 4
| Date | Title | Description |
| 09.08.2025 | Apreo Health Secures $130M to Revolutionize Emphysema Care | Apreo Health secured $130 million in Series B funding. This major investment propels its BREATHE Airway Scaffold, an innovative medical device for severe emphysema. The scaffold addresses lung hyperinflation, aiming to redefine treatment fo... |
| 08.08.2025 | Apreo Health: $130 Million Series B Raised For Developing Treatments For Severe Emphysema | Apreo Health, a clinical-stage medical device company focused on innovative treatments for severe emphysema, has announced the successful completion of an oversubscribed $130 million Series B financing round. This funding was jointly led by... |
| 07.08.2025 | Apreo Health Closes $130M in Series B Financing | Apreo Health, a Menlo Park, CA-based clinical-stage medical device company developing a novel treatment for severe emphysema, raised $130M in Series B funding. The round was led by Bain Capital Life Sciences and Norwest, with participation ... |
| - | Apreo Health | “Apreo Health” |